The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC

Despite recent advances in the development of novel personalized therapies, breast cancer continues to challenge physicians with resistance to various advanced therapies. The anticancer action of the anti-HER2 antibody, trastuzumab, involves antibody-dependent cell-mediated cytotoxicity (ADCC) by na...

Descripción completa

Detalles Bibliográficos
Autores principales: Guti, Eliza, Regdon, Zsolt, Sturniolo, Isotta, Kiss, Alexandra, Kovács, Katalin, Demény, Máté, Szöőr, Árpád, Vereb, György, Szöllősi, János, Hegedűs, Csaba, Polgár, Zsuzsanna, Virág, László
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374626/
https://www.ncbi.nlm.nih.gov/pubmed/35066605
http://dx.doi.org/10.1007/s00262-022-03146-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374626/
https://www.ncbi.nlm.nih.gov/pubmed/35066605
http://dx.doi.org/10.1007/s00262-022-03146-z

Ejemplares similares